Keck School Faculty

Parkash Singh Gill, MD
Parkash Singh Gill, MD
Professor of Medicine;Renette and Marshall Ezralow Family Chair in Cancer Therapeutics
1441 Eastlake Ave. Health Sciences Campus Los Angeles
Dr. Gill's primary research interest is in studying novel targets that are expressed both in tumor blood vessels as well as the tumor cell. He has demonstrated the ability to identify and validate novel targets, develop novel target therapeutics and collaborate with clinical investigators to conduct early stage clinical trials.

Dr. Gill has a strong history of clinical investigations and drug development. His clinical investigations led to the approval of three cancer drugs by the FDA. He also served on the advisory panel for the FDA advisory committee on biologics. Over the past several years his work has focused on the identification of novel cancer and cancer blood vessel targets, validation of the targets in various model systems including genetic mouse models.

Histological Validation of 11Carbon-Acetate Positron Emission Tomography/Computerized Tomography in Detecting Lymph Node Metastases in Prostate Cancer J Urol. 2019 Feb; 201(2):332-341. . View in PubMed

Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma Clin Cancer Res. 2018 Dec 01; 24(23):6099. . View in PubMed

Histologic Validation of 11Carbon-Acetate Positron Emission Tomography/Computer Tomography in Detecting Lymph Node Metastases in Prostate Cancer J Urol. 2018 Sep 12. . View in PubMed

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT Blood Adv. 2017 Sep 12; 1(20):1635-1644. . View in PubMed

Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series BJU Int. 2017 09; 120(3):401-408. . View in PubMed

Identifying aggressive prostate cancer foci using a DNA methylation classifier Genome Biol. 2017 01 12; 18(1):3. . View in PubMed

EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma PLoS One. 2017; 12(8):e0183161. . View in PubMed

GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice Proc Natl Acad Sci U S A. 2017 05 16; 114(20):E4020-E4029. . View in PubMed

Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas Sci Rep. 2016 Dec 12; 6:38792. . View in PubMed

Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas Sci Rep. 2016 12 12; 6:38792. . View in PubMed

Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model PLoS One. 2016; 11(3):e0152243. . View in PubMed

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways Oncotarget. 2015 Oct 06; 6(30):29143-60. . View in PubMed

PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B Mol Pharm. 2015 Oct 05; 12(10):3527-34. . View in PubMed

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer Sci Rep. 2015 Jun 15; 5:10641. . View in PubMed

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma Clin Cancer Res. 2015 Jun 01; 21(11):2601-12. . View in PubMed

Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159 J Nucl Med. 2015 Jun; 56(6):908-13. . View in PubMed

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model PLoS One. 2015; 10(7):e0131232. . View in PubMed

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy PLoS One. 2015; 10(8):e0134346. . View in PubMed

Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition Growth Factors. 2014 Dec; 32(6):202-6. . View in PubMed

Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft Mol Pharm. 2014 Nov 03; 11(11):3974-9. . View in PubMed

AXL mediates resistance to cetuximab therapy Cancer Res. 2014 Sep 15; 74(18):5152-64. . View in PubMed

Axl-targeted cancer imaging with humanized antibody h173 Mol Imaging Biol. 2014 Aug; 16(4):511-8. . View in PubMed

The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder PLoS One. 2014; 9(8):e105326. . View in PubMed

Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis Clin Cancer Res. 2013 Dec 15; 19(24):6802-11. . View in PubMed

EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab Mol Pharm. 2013 Dec 02; 10(12):4527-33. . View in PubMed

PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies J Nucl Med. 2013 Jul; 54(7):1094-100. . View in PubMed

EphB4 as a therapeutic target in mesothelioma BMC Cancer. 2013 May 30; 13:269. . View in PubMed

Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring Mol Pharm. 2013 Jan 07; 10(1):329-36. . View in PubMed

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target PLoS One. 2013; 8(7):e67668. . View in PubMed

Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers Cancer Res. 2013 Jan 01; 73(1):184-94. . View in PubMed

Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2 Cancer Res. 2012 Jul 15; 72(14):3582-92. . View in PubMed

Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA J Pharm Sci. 2012 Jun; 101(6):1969-84. . View in PubMed

Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues Biochem Biophys Res Commun. 2012 Feb 03; 418(1):173-9. . View in PubMed

Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis PLoS One. 2012; 7(1):e29863. . View in PubMed

Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling Br J Ophthalmol. 2010 Dec; 94(12):1668-73. . View in PubMed

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis BMC Cancer. 2010 Nov 23; 10:641. . View in PubMed

Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice Cancer Biol Ther. 2010 Nov 15; 10(10):1033-40. . View in PubMed

Immune evasion by Kaposi's sarcoma-associated herpesvirus Future Microbiol. 2010 Sep; 5(9):1349-65. . View in PubMed

Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma Mol Cancer Ther. 2010 Aug; 9(8):2377-88. . View in PubMed

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma Blood. 2010 Jul 15; 116(2):297-305. . View in PubMed

Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP J Biol Chem. 2010 May 14; 285(20):15065-75. . View in PubMed

Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth Am J Pathol. 2010 Apr; 176(4):2029-38. . View in PubMed

KSHV-induced notch components render endothelial and mural cell characteristics and cell survival Blood. 2010 Jan 28; 115(4):887-95. . View in PubMed

Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro Invest Ophthalmol Vis Sci. 2010 Jan; 51(1):543-52. . View in PubMed

Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression Cancer Res. 2009 May 01; 69(9):3736-45. . View in PubMed

The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade Blood. 2009 Jan 01; 113(1):254-63. . View in PubMed

Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli BMC Dev Biol. 2008 Dec 16; 8:117. . View in PubMed

Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos Blood. 2008 Sep 01; 112(5):1720-9. . View in PubMed

The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg. 2008 Sep; 134(9):985-91. . View in PubMed

Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma Blood. 2008 Apr 01; 111(7):3377-82. . View in PubMed

The origin of Kaposi sarcoma J Natl Cancer Inst. 2007 Jul 18; 99(14):1063. . View in PubMed

Identification of Hendra virus G glycoprotein residues that are critical for receptor binding J Virol. 2007 Jun; 81(11):5893-901. . View in PubMed

Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion Blood. 2007 Jun 01; 109(11):4753-60. . View in PubMed

Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties Mol Immunol. 2007 Apr; 44(11):3049-60. . View in PubMed

Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer Mol Cancer Res. 2007 Apr; 5(4):351-62. . View in PubMed

The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg. 2006 Oct; 132(10):1053-9. . View in PubMed

EphB4 provides survival advantage to squamous cell carcinoma of the head and neck Int J Cancer. 2006 Sep 15; 119(6):1236-48. . View in PubMed

Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am J Pathol. 2006 Jul; 169(1):279-93. . View in PubMed

Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy J Clin Oncol. 2006 Apr 10; 24(11):1712-9. . View in PubMed

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol. 2006 Apr; 175(4):1245-52. . View in PubMed

The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth Blood. 2006 Mar 15; 107(6):2330-8. . View in PubMed

Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization Invest Ophthalmol Vis Sci. 2005 Dec; 46(12):4772-9. . View in PubMed

Up-regulation of EphB4 in mesothelioma and its biological significance Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. . View in PubMed

EphB4 expression and biological significance in prostate cancer Cancer Res. 2005 Jun 01; 65(11):4623-32. . View in PubMed

Molecular prognostic factors in bladder cancer BJU Int. 2005 Apr; 95(6):739-42. . View in PubMed

Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team J Clin Oncol. 2005 Feb 10; 23(5):990-8. . View in PubMed

VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer Surgery. 2005 Feb; 137(2):192-9. . View in PubMed

Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium Blood. 2005 Feb 01; 105(3):1310-8. . View in PubMed

Th1 and Th2 cytokines and IgE levels in identical twins with varying levels of cigarette consumption J Clin Immunol. 2004 Nov; 24(6):617-22. . View in PubMed

VEGF and myeloid leukemias Leuk Res. 2004 Jul; 28(7):675-7. . View in PubMed

Alpha-chemokine-mediated signal transduction in human Kaposi's sarcoma spindle cells Biochim Biophys Acta. 2004 May 03; 1691(2-3):129-39. . View in PubMed

IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma Blood. 2004 Apr 15; 103(8):3216-21. . View in PubMed

Expression of EphB4 in head and neck squamous cell carcinoma Ear Nose Throat J. 2003 Nov; 82(11):866, 869-70, 887. . View in PubMed

Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan Int J Cancer. 2003 Sep 10; 106(4):528-33. . View in PubMed

Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops Int J Cancer. 2003 May 01; 104(5):603-10. . View in PubMed

A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma Cancer. 2002 Dec 15; 95(12):2555-61. . View in PubMed

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma Cancer. 2002 Jul 01; 95(1):147-54. . View in PubMed

Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer J Gastrointest Surg. 2002 Mar-Apr; 6(2):159-66; discussion 166. . View in PubMed

Multidrug resistance (MDR-1) expression in AIDS-related lymphomas Leuk Res. 2002 Feb; 26(2):121-7. . View in PubMed

Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor Am J Pathol. 2002 Jan; 160(1):23-9. . View in PubMed

Powered by SC CTSI
Go to Top